Show simple item record

dc.contributor.authorDierssen Sotos, Trinidad 
dc.contributor.authorGómez Acebo, Inés 
dc.contributor.authorPalazuelos Calderón, Camilo
dc.contributor.authorFernández- Navarro, Pablo
dc.contributor.authorAltzibar, Jone M.
dc.contributor.authorGonzález-Donquiles, Carmen
dc.contributor.authorArdanaz, Eva
dc.contributor.authorBustamante, Mariona
dc.contributor.authorAlonso Molero, Jessica
dc.contributor.authorVidal, Carmen
dc.contributor.authorBayo-Calero, Juan
dc.contributor.authorTardón, Adonina
dc.contributor.authorSalas, Dolores
dc.contributor.authorMarcos-Gragera, Rafael
dc.contributor.authorMoreno, Víctor
dc.contributor.authorRodríguez Cundín, María Paz 
dc.contributor.authorCastaño Vinyals, Gemma
dc.contributor.authorEderra, María
dc.contributor.authorVilorio-Marqués, Laura
dc.contributor.authorLlorca Díaz, Francisco Javier 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.description.abstractA breast-risk score, published in 2016, was developed in white-American women using 92 genetic variants (GRS92), modifiable and non-modifiable risk factors. With the aim of validating the score in the Spanish population, 1,732 breast cancer cases and 1,910 controls were studied. The GRS92, modifiable and non-modifiable risk factor scores were estimated via logistic regression. SNPs without available genotyping were simulated as in the aforementioned 2016 study. The full model score was obtained by combining GRS92, modifiable and non-modifiable risk factor scores. Score performances were tested via the area under the ROC curve (AUROC), net reclassification index (NRI) and integrated discrimination improvement (IDI). Compared with non-modifiable and modifiable factor scores, GRS92 had higher discrimination power (AUROC: 0.6195, 0.5885 and 0.5214, respectively). Adding the non-modifiable factor score to GRS92 improved patient classification by 23.6% (NRI?=?0.236), while the modifiable factor score only improved it by 7.2%. The full model AUROC reached 0.6244. A simulation study showed the ability of the full model for identifying women at high risk for breast cancer. In conclusion, a model combining genetic and risk factors can be used for stratifying women by their breast cancer risk, which can be applied to individualizing genetic counseling and screening recommendations.es_ES
dc.description.sponsorshipThe study was partially funded by the “Acción Transversal del Cancer” project, approved by the Spanish Council of Ministers on the 11th October 2007, by the Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PI09/00773-Cantabria, PI09/01286-León, PI09/01903-Valencia, PI09/02078-Huelva, PI09/01662-Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219), by the Fundación Marqués de Valdecilla (API 10/09), by the ICGC International Cancer Genome Consortium CLL (The ICGC CLL-Genome Project is funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)), by the Junta de Castilla y León (LE22A10-2), by the Consejería de Salud of the Junta de Andalucía (2009-S0143), by the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), by the Recercaixa (2010ACUP 00310), by the Regional Government of the Basque Country, by the European Commission grants FOOD-CT-2006-036224-HIWATE, by the Spanish Association Against Cancer (AECC) Scientific Foundation and by the Catalan Government DURSI grant 2009SGR1489.es_ES
dc.format.extent8 p.es_ES
dc.publisherNature Publishing Groupes_ES
dc.rightsAttribution 4.0 Internationales_ES
dc.sourceSci Rep. 2018 Feb 14;8(1):3036es_ES
dc.titleValidating a breast cancer score in Spanish women. The MCC-Spain studyes_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 InternationalExcept where otherwise noted, this item's license is described as Attribution 4.0 International